Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
Delayed Quote. Delayed Nasdaq - 12/01 04:00:00 pm
123.23 USD   +1.79%
11/27EXACT SCIENCES CORP : Other Events (form 8-K)
AQ
11/10EXACT SCIENCES : Code of Business Conduct and Ethics
PU
11/10EXACT SCIENCES : Policy Governing Director Nominations
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Exact Sciences : to buy cancer-screening firm Thrive Earlier Detection in $2.15 bln deal

10/27/2020 | 07:19am EST

Oct 27 (Reuters) - Exact Sciences Corp said on Tuesday it would buy cancer-screening firm Thrive Earlier Detection Corp in a cash-and-stock deal that could be valued up to $2.15 billion.

Exact Sciences said it expects to expand its cancer detection portfolio with Thrive's lead early-stage screening test, CancerSEEK, which successfully detected 10 different types of cancer in a 10,000-patient study in April.

Thrive will get $1.7 billion, comprising 65% of Exact Sciences' common stock and 35% in cash, under terms of the deal. An additional $450 million is payable upon completion of certain milestones.

The companies expect to close the deal in the first quarter of 2021. (Reporting by Trisha Roy in Bengaluru; Editing by Ramakrishnan M.)


© Reuters 2020
All news about EXACT SCIENCES CORPORATION
11/27EXACT SCIENCES CORP : Other Events (form 8-K)
AQ
11/10EXACT SCIENCES : Code of Business Conduct and Ethics
PU
11/10EXACT SCIENCES : Policy Governing Director Nominations
PU
10/27EXACT SCIENCES : to buy cancer-screening firm Thrive Earlier Detection in $2.15 ..
RE
10/27EXACT SCIENCES : Infographic
PU
10/27EXACT SCIENCES : 3Q Earnings Snapshot
AQ
10/27EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
10/07PFIZER : Will Continue Helping Exact Sciences With Cologuard Promotion Through 2..
DJ
09/21EXACT SCIENCES CORP : Change in Directors or Principal Officers (form 8-K)
AQ
07/31EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
More news
Financials (USD)
Sales 2020 1 451 M - -
Net income 2020 -379 M - -
Net cash 2020 182 M - -
P/E ratio 2020 -49,6x
Yield 2020 -
Capitalization 19 252 M 19 252 M -
EV / Sales 2020 13,1x
EV / Sales 2021 10,4x
Nbr of Employees 4 110
Free-Float 99,1%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Average target price 150,43 $
Last Close Price 121,06 $
Spread / Highest target 33,0%
Spread / Average Target 24,3%
Spread / Lowest Target 15,6%
EPS Revisions
Managers
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Ana Hooker Senior Vice President-Operations
Jeffrey Thomas Elliott Chief Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz SVP-Clinical & Regulatory Affairs
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION30.90%19 252
GUARDANT HEALTH, INC.55.00%12 109
INVITAE CORPORATION207.81%8 773
ADAPTIVE BIOTECHNOLOGIES CORPORATION61.16%6 595
IOVANCE BIOTHERAPEUTICS, INC.40.21%5 693
SEEGENE INC--.--%4 408